The federal Project Grant award R01HL174928, sponsored by the National Heart, Lung, and Blood Institute (NHLBI) through the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at Boston Children's Hospital to study the role of endothelial epsins in regulating myocardial ischemia and heart regeneration. The $833,681 award, with a period of performance from July 2024 to June 2028, aims to decipher the molecular mechanisms by which targeting cardiac endothelial epsins can stimulate new blood vessel growth and enhance heart repair following myocardial infarction. The research leverages newly developed single-cell RNA sequencing technologies to investigate how the loss of endothelial epsins potentiates endothelial cell expansion and vascularization in neonatal and adult hearts, with the goal of uncovering novel regulatory mechanisms and identifying new therapeutic targets for ischemic heart diseases and heart failure.
Generated 3/4/25, 2:53 AM